Isabelle E Bauer1, Michaela C Pascoe2, Bianca Wollenhaupt-Aguiar3, Flavio Kapczinski4, Jair C Soares5. 1. University of Texas Health Science Center at Houston, Department of Psychiatry and Behavioral Sciences, 77054 Houston, TX, United States. Electronic address: Isabelle.E.Bauer@uth.tmc.edu. 2. Department of Clinical Neuroscience and Rehabilitation, Sahlgrenska Academy at University of Gothenburg, Box 440, 40530 Gothenburg, Sweden. 3. Laboratório de Psiquiatria Molecular, Instituto Nacional de Ciência e Tecnologia - Translacional em Medicina (INCT), Hospital de Clínicas de Porto Alegre, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. 4. University of Texas Health Science Center at Houston, Department of Psychiatry and Behavioral Sciences, 77054 Houston, TX, United States; Laboratório de Psiquiatria Molecular, Instituto Nacional de Ciência e Tecnologia - Translacional em Medicina (INCT), Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. 5. University of Texas Health Science Center at Houston, Department of Psychiatry and Behavioral Sciences, 77054 Houston, TX, United States.
Abstract
OBJECTIVES: Recent studies have pointed to neuroinflammation, oxidative stress and neurotrophic factors as key mediators in the pathophysiology of mood disorders. Little is however known about the cascade of biological episodes underlying the cognitive deficits observed during the acute and euthymic phases of bipolar disorder (BD). The aim of this review is to assess the potential association between cognitive impairment and biomarkers of inflammation, oxidative stress and neurotrophic activity in BD. METHODS: Scopus (all databases), Pubmed and Ovid Medline were systematically searched with no language or year restrictions, up to November 2013, for human studies that collected both inflammatory markers and cognitive data in BD. Selected search terms were bipolar disorder, depression, mania, psychosis, inflammatory, cognitive and neurotrophic. RESULTS: Ten human studies satisfied the criteria for consideration. The findings showed that high levels of peripheral inflammatory-cytokine, oxidative stress and reduced brain derived neurotrophic factor (BDNF) levels were associated with poor cognitive performance. The BDNF val66met polymorphism is a potential vulnerability factor for cognitive impairment in BD. CONCLUSIONS: Current data provide preliminary evidence of a link between the cognitive decline observed in BD and mechanisms of neuroinflammation and neuroprotection. The identification of BD specific inflammatory markers and polymorphisms in inflammatory response genes may be of assistance for therapeutic intervention.
OBJECTIVES: Recent studies have pointed to neuroinflammation, oxidative stress and neurotrophic factors as key mediators in the pathophysiology of mood disorders. Little is however known about the cascade of biological episodes underlying the cognitive deficits observed during the acute and euthymic phases of bipolar disorder (BD). The aim of this review is to assess the potential association between cognitive impairment and biomarkers of inflammation, oxidative stress and neurotrophic activity in BD. METHODS: Scopus (all databases), Pubmed and Ovid Medline were systematically searched with no language or year restrictions, up to November 2013, for human studies that collected both inflammatory markers and cognitive data in BD. Selected search terms were bipolar disorder, depression, mania, psychosis, inflammatory, cognitive and neurotrophic. RESULTS: Ten human studies satisfied the criteria for consideration. The findings showed that high levels of peripheral inflammatory-cytokine, oxidative stress and reduced brain derived neurotrophic factor (BDNF) levels were associated with poor cognitive performance. The BDNFval66met polymorphism is a potential vulnerability factor for cognitive impairment in BD. CONCLUSIONS: Current data provide preliminary evidence of a link between the cognitive decline observed in BD and mechanisms of neuroinflammation and neuroprotection. The identification of BD specific inflammatory markers and polymorphisms in inflammatory response genes may be of assistance for therapeutic intervention.
Authors: Bo Cao; Isabelle E Bauer; Ajaykumar N Sharma; Benson Mwangi; Thomas Frazier; Luca Lavagnino; Giovana B Zunta-Soares; Consuelo Walss-Bass; David C Glahn; Flavio Kapczinski; David A Nielsen; Jair C Soares Journal: J Affect Disord Date: 2016-03-10 Impact factor: 4.839
Authors: Samira S Valvassori; Wilson R Resende; Roger B Varela; Camila O Arent; Fernanda F Gava; Bruna R Peterle; Gustavo C Dal-Pont; André F Carvalho; Monica L Andersen; João Quevedo Journal: Mol Neurobiol Date: 2017-02-06 Impact factor: 5.590
Authors: Taiane de A Cardoso; Isabelle E Bauer; Karen Jansen; Robert Suchting; Giovana Zunta-Soares; João Quevedo; David C Glahn; Jair C Soares Journal: Psychiatry Res Date: 2016-06-29 Impact factor: 3.222
Authors: Dwight F Newton; Melanie R Naiberg; Ana C Andreazza; Gustavo Scola; Daniel P Dickstein; Benjamin I Goldstein Journal: Psychopharmacology (Berl) Date: 2016-12-12 Impact factor: 4.530